|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 20, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash | |||||||
| Prepaid expenses | |||||||
| Prepaid Consulting Services | |||||||
| Other current assets | |||||||
| Total Current Assets | |||||||
| Other assets | |||||||
| Deferred offering costs | |||||||
| Investments held in the Trust Account | |||||||
| Total Assets | |||||||
| LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S DEFICIT | |||||||
| Liabilities | |||||||
| Current Liabilities: | |||||||
| Accounts payable and accrued expenses | |||||||
| Accrued offering costs | |||||||
| Advances from related party | |||||||
| Franchise tax payable | |||||||
| Excise tax payable | |||||||
| Income tax payable | |||||||
| Note payable—Sponsor | |||||||
| Total Current Liabilities | |||||||
| Other long-term liabilities | |||||||
| Deferred underwriting commission | |||||||
| Total Liabilities | |||||||
| Class A common stock subject to possible redemption; 4,644,647 and 23,000,000 shares outstanding as of September 30, 2023 and December 31, 2022, respectively (at redemption price) | |||||||
| Stockholders' deficit: | |||||||
| Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |||||||
| Common Stock, Value, Issued | |||||||
| Common Class A | |||||||
| Common Class B | |||||||
| Additional paid-in capital | |||||||
| Accumulated deficit | |||||||
| Total Stockholders' Deficit | |||||||
| Total Liabilities, Common Stock subject to Possible Redemption and Stockholders' Deficit |
Loading...